Skip to content
Ozempic(semaglutide)
Ozempic, Rybelsus, Wegovy (semaglutide) is a protein pharmaceutical. Semaglutide was first approved as Ozempic on 2017-12-05. It has been approved in Europe to treat diabetes mellitus, obesity, overweight, and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
diagnosisD003933
physiological phenomenaD010829
Trade Name
FDA
EMA
Ozempic, Rybelsus, Wegovy
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Semaglutide
Tradename
Company
Number
Date
Products
OZEMPICKazia TherapeuticsN-209637 RX2017-12-05
4 products, RLD, RS
RYBELSUSKazia TherapeuticsN-213051 RX2019-09-20
3 products, RLD, RS
WEGOVYKazia TherapeuticsN-215256 RX2021-06-04
5 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ozempicNew Drug Application2022-11-29
rybelsusNew Drug Application2020-01-16
wegovyNew Drug Application2023-02-14
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
SEMAGLUTIDE, WEGOVY, NOVO
2025-12-23NPP
2024-06-04NP
SEMAGLUTIDE, OZEMPIC, NOVO
2025-03-28D-185
2023-01-16I-822
SEMAGLUTIDE, RYBELSUS, NOVO
2023-01-16M-252
Patent Expiration
Patent
Expires
Flag
FDA Information
Semaglutide, Wegovy, Novo
113181912041-02-17DPU-3162
108886052038-08-24DPU-3162
97640032033-06-21U-3161
Semaglutide, Rybelsus, Novo
102789232034-05-02U-2628
109331202033-03-15DP
92781232031-12-16DPU-2628
100860472031-12-16DP
109600522031-12-16DP
113829572031-12-16DP
Semaglutide, Ozempic, Novo
103354622033-06-21DPU-2580
91322392032-02-01DP
81293432031-12-05DS, DPU-2202, U-2628, U-3355, U-3469
94571542027-09-29DP
96876112027-02-27DP
RE463632026-08-03DP
89203832026-07-17DP
97759532026-07-17DP
102201552026-07-17DP
110970632026-07-17DP
85361222026-03-20DS, DPU-2202, U-2628, U-3355, U-3469
91080022026-01-20DP
96161802026-01-20DP
98617572026-01-20DP
103576162026-01-20DP
103766522026-01-20DP
113116792026-01-20DP
86849692025-10-20DP
114464432025-10-20DP
81148332025-08-13DP
77629942024-05-23DP
85798692023-06-30DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
— A10BJ06: Semaglutide
HCPCS
No data
Clinical
Clinical Trials
300 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E114310471836154
ObesityD009765EFO_0001073E66.9138267458
Healthy volunteers/patients—372—2—41
OverweightD050177E66.3101152—28
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.811812—11
Pediatric obesityD063766—311—4
Prediabetic stateD011236EFO_1001121R73.03—1—113
Coronary artery diseaseD003324I25.1——11—2
Atrial fibrillationD001281EFO_0000275I48.0——11—2
SchizophreniaD012559EFO_0000692F20—1—1—2
Show 11 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nutrition disordersD009748EFO_0001069212——5
Alcoholic fatty liverD005235K70.0—41——5
Type 1 diabetes mellitusD003922EFO_0001359E10—21—13
Chronic renal insufficiencyD051436N18—21——3
DiseaseD004194EFO_0000408R69——1——1
Alzheimer diseaseD000544EFO_0000249F03——1——1
Diabetic nephropathiesD003928EFO_0000401——1——1
Peripheral arterial diseaseD058729EFO_0004265——1——1
AlbuminuriaD000419EFO_0004285R80.9——1——1
Metabolic syndromeD024821EFO_0000195E88.81——1——1
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20—1——12
Digestive system diseasesD004066EFO_0000405K92.911———2
Metabolic bone diseasesD001851HP_000093811———1
Covid-19D000086382U07.1—1———1
Major depressive disorderD003865EFO_0003761F22—1———1
Parkinson diseaseD010300EFO_0002508G20—1———1
Glucose intoleranceD018149HP_0000833R73.03—1———1
AsthmaD001249EFO_0000270J45—1———1
Ischemic strokeD000083242—1———1
Tobacco use disorderD014029F17—1———1
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N191————1
HypercholesterolemiaD006937HP_00031241————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AtherosclerosisD050197EFO_0003914I25.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSEMAGLUTIDE
INNsemaglutide
Description
Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.
Classification
Protein
Drug classpeptides: glucagon-like peptide (GLP) analogs
Image (chem structure or protein)SEMAGLUTIDE
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID910463-68-2
RxCUI1991302
ChEMBL IDCHEMBL2108724
ChEBI ID—
PubChem CID56843331
DrugBankDB13928
UNII ID53AXN4NNHX (ChemIDplus, GSRS)
Target
Agency Approved
GLP1R
GLP1R
Organism
Homo sapiens
Gene name
GLP1R
Gene synonyms
NCBI Gene ID
2740
Protein name
glucagon-like peptide 1 receptor
Protein synonyms
GLP-1 receptor, GLP1 receptor, seven transmembrane helix receptor
Uniprot ID
Q99669
Mouse ortholog
Glp1r (14652)
glucagon-like peptide 1 receptor (Q1JQR8)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Rybelsus - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Ozempic - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Wegovy - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,004 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ozempic, Rybelsus, Wegovy
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
184 adverse events reported
View more details